Fingerprint
Dive into the research topics of 'Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Joleen Hubbard, Charles Erlichman, David O. Toft, Rui Qin, Bridget A. Stensgard, Sara Felten, Cynthia Ten Eyck, Gretchen Batzel, S. Percy Ivy, Paul Haluska
Research output: Contribution to journal › Article › peer-review
29
Scopus
citations